ArticleAntimicrobial agents and chemotherapy2011
High-throughput Giardia lamblia viability assay using bioluminescent ATP content measurements.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 48 citations in OpenAlex.
- 5-Nitrothiazol-Clofibric Acid Analogs as Potent Agents Against Nitazoxanide-ResistantMolecules (Basel, Switzerland) · 2026Article
- TATA-Binding Protein-Based Virtual Screening of FDA Drugs Identified New Anti-Giardiasis Agents.International journal of molecular sciences · 2024Article
- Identification of Fungus-Derived Natural Products as New Antigiardial Scaffolds.Microbiology spectrum · 2023Article
- Repurposing the Kinase Inhibitor Mavelertinib for Giardiasis Therapy.Antimicrobial agents and chemotherapy · 2022Article
- Recent Advances in Cancer Drug Discovery Through the Use of Phenotypic Reporter Systems, Connectivity Mapping, and Pooled CRISPR Screening.Frontiers in pharmacology · 2022Review
- Discovery and Preclinical Development of Antigiardiasis Fumagillol Derivatives.Antimicrobial agents and chemotherapy · 2020Article
- Methionyl-tRNA synthetase inhibitor has potent in vivo activity in a novel Giardia lamblia luciferase murine infection model.The Journal of antimicrobial chemotherapy · 2020Article
- An image-based Pathogen Box screen identifies new compounds with anti-Giardia activity and highlights the importance of assay choice in phenotypic drug discovery.International journal for parasitology. Drugs and drug resistance · 2020Article
- Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity.PLoS neglected tropical diseases · 2020Article
- Recent Advances in the Discovery of Novel Antiprotozoal Agents.Molecules (Basel, Switzerland) · 2019Review
- Drug repurposing for antimicrobial discovery.Nature microbiology · 2019Review
- Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota.Nature communications · 2018Article
- Screening of the Pathogen Box for inhibitors with dual efficacy against Giardia lamblia and Cryptosporidium parvum.PLoS neglected tropical diseases · 2018Article
- Treatment-refractory giardiasis: challenges and solutions.Infection and drug resistance · 2018Review
- Susceptibility Testing of Medically Important Parasites.Clinical microbiology reviews · 2017Review
- Antifungal Resistance, Metabolic Routes as Drug Targets, and New Antifungal Agents: An Overview about Endemic Dimorphic Fungi.Mediators of inflammation · 2017Review
- Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen.Nature medicine · 2016Article
- Inhibitors of methionyl-tRNA synthetase have potent activity against Giardia intestinalis trophozoites.Antimicrobial agents and chemotherapy · 2015Article
- Drug Development Against the Major Diarrhea-Causing Parasites of the Small Intestine, Cryptosporidium and Giardia.Frontiers in microbiology · 2015Review
- Discovery of novel antigiardiasis drug candidates.Antimicrobial agents and chemotherapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
The human pathogen Giardia lamblia is an anaerobic protozoan parasite that causes giardiasis, one of the most common diarrheal diseases worldwide. Although several drugs are available for the treatment of giardiasis, drug resistance has been reported and is likely to increase, and recurrent infections are common. The search for new drugs that can overcome the drug-resistant strains of Giardia is an unmet medical need. New drug screen methods can facilitate the drug discovery process and aid with the identification of new drug targets. Using a bioluminescent ATP content assay, we have developed a phenotypic drug screen method to identify compounds that act against the actively growing trophozoite stage of the parasite. This assay is homogeneous, robust, and suitable for high-throughput screening of large compound collections. A screen of 4,096 pharmacologically active small molecules and approved drugs revealed 43 compounds with selective anti-Giardia properties, including 32 previously reported and 11 novel anti-Giardia agents. The most potent novel compound was fumagillin, which showed 50% inhibitory concentrations of 10 nM against the WB isolate and 2 nM against the GS isolate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.